Research Analysts Issue Forecasts for CHRS Q3 Earnings

Key Points

• HC Wainwright forecasts a Q3 2026 loss of $0.22 per share for Coherus Oncology and projects continued losses through 2029, with profitability of $0.19 per share expected in 2030.
• Analyst sentiment is mixed but generally favorable: HC Wainwright maintains a Buy rating, while MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $11.00.
• CHRS shares opened at $0.83, near their 52-week low of $0.81 and well below the 50-day and 200-day moving averages; the company remains unprofitable despite recently exceeding quarterly EPS expectations.

Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) - HC Wainwright issued their Q3 2026 earnings estimates for Coherus Oncology in a research note issued on Thursday, October 29th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of ($0.22) for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Coherus Oncology's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Coherus Oncology's Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.48) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.19 EPS.

Separately, Weiss Ratings raised shares of Coherus Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, October 26th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.00.

Coherus Oncology Price Performance

Shares of NASDAQ CHRS opened at $0.83 on Monday. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.53. Coherus Oncology has a 52-week low of $0.81 and a 52-week high of $2.62. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77. The stock has a market cap of $128.25 million, a P/E ratio of -0.81 and a beta of 1.03.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.06. The business had revenue of $14.31 million during the quarter, compared to analyst estimates of $14.41 million. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 222.75%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Spark Investment Management LLC purchased a new stake in shares of Coherus Oncology in the second quarter valued at approximately $25,000. Jefferies Financial Group Inc. bought a new stake in shares of Coherus Oncology during the 2nd quarter worth about $353,000. Corient Private Wealth LP acquired a new stake in shares of Coherus Oncology in the second quarter worth $140,000. Bank of America Corp DE acquired a new stake in shares of Coherus Oncology in the second quarter worth about $424,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Coherus Oncology during the 2nd quarter worth approximately $131,000. 72.82% of the stock is currently owned by institutional investors and hedge funds.

More Coherus Oncology News

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: New data for tagmokitug reportedly support advancing the program into a broader study. The update could improve investor confidence in Coherus Oncology’s pipeline and provide a potential catalyst if expanded testing confirms the treatment’s benefit. Coherus Oncology stock: Tagmokitug data support broader study
• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating. Its forecasts anticipate Coherus Oncology’s losses narrowing from an estimated $0.91 per share in fiscal 2026 to $0.63 in fiscal 2027, $0.48 in fiscal 2028 and $0.19 in fiscal 2029, before turning profitable at $0.19 per share in fiscal 2030. This projected improvement offers a longer-term bullish argument for the stock. HC Wainwright Initiates Coverage on Coherus Oncology
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, including estimated EPS of negative $0.22 in Q3 2026 and negative $0.21 in Q4 2026, followed by losses ranging from $0.17 to $0.13 per share during 2027. The estimates provide a clearer outlook but do not imply near-term profitability.
• Negative Sentiment: HC Wainwright’s fiscal 2026 loss estimate of $0.91 per share is slightly worse than the broader consensus estimate of $0.87. Continued negative earnings could weigh on sentiment, particularly while CHRS remains well below its 50-day and 200-day moving averages and faces biotechnology-sector financing and execution risks.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.